Investment Thesis — Reinsurance Group of America, Incorporated
The market undervalues RGA's ability to compound earnings through disciplined risk selection and capital allocation, mispricing its resilience to macro volatility. Investors focus on headline multiples, ignoring the structural shift toward higher-margin longevity and health reinsurance, which insulates RGA from traditional mortality risk shocks.
Catalysts
- Accelerated growth in longevity and health reinsurance premiums
- Share buybacks or special dividends from excess capital
- Positive regulatory developments supporting capital efficiency
Risk Factors
- Unexpected mortality spikes from pandemics or disasters
- Adverse regulatory changes increasing capital requirements
- Failure to scale new segments profitably
Key Debates
RGA's Fwd P/E re-rates to 10x by Q1 2025 on sustained 15.5% growth.
Short float drops below 4% by Q1 2025 on earnings stability.
RGA reaches $238.50 analyst target by Q4 2024.